TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Plain-language summary
This trial is testing TR115 (an EZH2 inhibitor) compared with investigator's choice of standard agents for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
TR115 (DRUG): TR115 will be administered orally twice daily until documented disease progression, unacceptable toxicity, withdrawal of consent, death, or study discontinuation. | Investigator's Choice (DRUG): Investigator's choice treatment with chidamide, golidocitinib, mitoxantrone hydrochloride liposome, or gemcitabine hydrochloride administered according to the respective approved prescribing information.
TR115, Investigator's Choice
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details